0.2502USDMkt Cap: —P/E: —1d ago
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead…
Industry Peers
Healthcare$1.14TUSDP/E 43.0
$658.89BUSDP/E 31.7
$462.68BUSDP/E 74.0
$345.19BUSDP/E 24.7
$375.50BUSDP/E 122.7
$348.81BUSDP/E 25.0
$283.47BUSDP/E 22.7
$276.41BUSDP/E 23.7
$234.02BUSDP/E 25.0
$240.45BUSDP/E 24.5
$238.75BUSDP/E 27.4
$226.85BUSDP/E 33.1
$190.75BUSDP/E 11.3
$198.81BUSDP/E 36.9
$183.02BUSD
$160.96BUSDP/E 37.2
$142.58BUSDP/E 38.5
$151.78BUSDP/E 38.6
$142.49BUSDP/E 45.6
$130.23BUSDP/E 32.1
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-117.30M $
Revenue/Share—
Last Price0.2502 USD
Fiscal Year End—
MR Quarter—
Employees81
CountryUS
SectorHealthcare
Industry—
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.07
EPS (TTM)—
EPS (Forward)—
52W Range
—
52W High0.2502 USD
52W Low0.2502 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-69.94%
ROA-52.97%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-99.24M $
CapEx (TTM)1.49M $
FCF Margin—
FCF Yield—
Net Debt-225.11M $
Net Debt/EBITDA1.71
Balance Sheet
Debt/Equity0.19
Current Ratio12.57
Quick Ratio12.17
Book Value/Sh3.809 USD
Cash/Share3.858 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float32.73M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta-0.28
S&P 52W Chg21.00%
Avg Vol (30d)100
Avg Vol (10d)—
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—